Drugs / TQA3526
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04278820 | Mar 2020 → Nov 2022 | primary biliary cholangitis | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TQA3526 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04278820 ↗ |
| Action | Activate | “FXR agonist” NCT04278820 ↗ |
| Route | Oral | “Tablet(s) administered orally once daily” NCT04278820 ↗ |